BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jin B, Wang D, Lewandowski RJ, Riaz A, Ryu RK, Sato KT, Larson AC, Salem R, Omary RA. Chemoembolization endpoints: effect on survival among patients with hepatocellular carcinoma. AJR Am J Roentgenol. 2011;196:919-928. [PMID: 21427346 DOI: 10.2214/AJR.10.4770] [Cited by in Crossref: 40] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
Number Citing Articles
1 Mueller K, Fahrig R, Manhart M, Deuerling-zheng Y, Rosenberg J, Moore T, Ganguly A, Kothary N. Reproducibility of Parenchymal Blood Volume Measurements Using an Angiographic C-arm CT System. Academic Radiology 2016;23:1441-5. [DOI: 10.1016/j.acra.2016.08.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
2 Kwan J, Pua U. Review of Intra-Arterial Therapies for Colorectal Cancer Liver Metastasis. Cancers (Basel) 2021;13:1371. [PMID: 33803606 DOI: 10.3390/cancers13061371] [Reference Citation Analysis]
3 Prajapati HJ, Kim HS. Treatment algorithm based on the multivariate survival analyses in patients with advanced hepatocellular carcinoma treated with trans-arterial chemoembolization. PLoS One 2017;12:e0170750. [PMID: 28170405 DOI: 10.1371/journal.pone.0170750] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
4 He EX, Nie ZS, Zhu MY, Lin HF, Wang L, Lin ZD, Xie XJ, Li MS. Association of alpha fetoprotein levels and presence of parasitical blood vessels with response to TACE in patients with advanced liver cancer. Shijie Huaren Xiaohua Zazhi 2013; 21(20): 1931-1938 [DOI: 10.11569/wcjd.v21.i20.1931] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Chang PY, Huang CC, Hung CH, Yu CY, Wu DK, Hwang JI, Liang PC, Wu RH, Tsai WL, Lin YJ, Liu YS, Liang HL, Lee RC, Chen CH. Multidisciplinary Taiwan Consensus Recommendations for the Use of DEBDOX-TACE in Hepatocellular Carcinoma Treatment. Liver Cancer 2018;7:312-22. [PMID: 30488021 DOI: 10.1159/000487608] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Pirasteh A, Sorra EA, Marquez H, Sibley RC, Fielding JR, Vij A, Rich NE, Arroyo A, Yopp AC, Khatri G, Singal AG, Yokoo T. LI-RADS treatment response algorithm after first-line DEB-TACE: reproducibility and prognostic value at initial post-treatment CT/MRI. Abdom Radiol (NY) 2021;46:3708-16. [PMID: 33755735 DOI: 10.1007/s00261-021-03043-6] [Reference Citation Analysis]
7 Lewis AL, Willis SL, Dreher MR, Tang Y, Ashrafi K, Wood BJ, Levy EB, Sharma KV, Negussie AH, Mikhail AS. Bench-to-clinic development of imageable drug-eluting embolization beads: finding the balance. Future Oncol 2018;14:2741-60. [PMID: 29944007 DOI: 10.2217/fon-2018-0196] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
8 Meram E, Harari C, Shaughnessy G, Wagner M, Brace CL, Mistretta CA, Speidel MA, Laeseke PF. Quantitative 4D-Digital Subtraction Angiography to Assess Changes in Hepatic Arterial Flow during Transarterial Embolization: A Feasibility Study in a Swine Model. J Vasc Interv Radiol 2019;30:1286-92. [PMID: 31160194 DOI: 10.1016/j.jvir.2019.01.018] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
9 Bonekamp S, Li Z, Geschwind JF, Halappa VG, Corona-Villalobos CP, Reyes D, Pawlik TM, Bonekamp D, Eng J, Kamel IR. Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. Part I. Identification and validation of volumetric functional response criteria. Radiology 2013;268:420-30. [PMID: 23616631 DOI: 10.1148/radiol.13122307] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 3.3] [Reference Citation Analysis]
10 Wang D, Gaba RC, Jin B, Lewandowski RJ, Riaz A, Memon K, Ryu RK, Sato KT, Kulik LM, Mulcahy MF, Larson AC, Salem R, Omary RA. Perfusion reduction at transcatheter intraarterial perfusion MR imaging: a promising intraprocedural biomarker to predict transplant-free survival during chemoembolization of hepatocellular carcinoma. Radiology 2014;272:587-97. [PMID: 24678859 DOI: 10.1148/radiol.14131311] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
11 Chang KH, Hwang ZA, Chang PY, Lin HH, Shih YL, Chang WC, Huang GS, Hsu HH. Predictive imaging for tumor response to drug-eluting microsphere transarterial chemoembolization in patients with BCLC-C advanced hepatocellular carcinoma. Sci Rep 2019;9:20032. [PMID: 31882969 DOI: 10.1038/s41598-019-56545-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Kim AY, Frantz S, Krishnan P, DeMulder D, Caridi T, Lynskey GE, Spies JB. Short-term imaging response after drug-eluting embolic trans-arterial chemoembolization delivered with the Surefire Infusion System® for the treatment of hepatocellular carcinoma. PLoS One 2017;12:e0183861. [PMID: 28863147 DOI: 10.1371/journal.pone.0183861] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
13 Hasdemir DB, Dávila LA, Schweitzer N, Meyer BC, Koch A, Vogel A, Wacker F, Rodt T. Evaluation of CT vascularization patterns for survival prognosis in patients with hepatocellular carcinoma treated by conventional TACE. Diagn Interv Radiol 2017;23:217-22. [PMID: 28256449 DOI: 10.5152/dir.2016.16006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
14 Hoffman C, Periyasamy S, Longhurst C, Medero R, Roldan-Alzate A, Speidel MA, Laeseke PF. A technique for intra-procedural blood velocity quantitation using time-resolved 2D digital subtraction angiography. CVIR Endovasc 2021;4:11. [PMID: 33411087 DOI: 10.1186/s42155-020-00199-y] [Reference Citation Analysis]
15 Dodson RM, Firoozmand A, Hyder O, Tacher V, Cosgrove DP, Bhagat N, Herman JM, Wolfgang CL, Geschwind JF, Kamel IR, Pawlik TM. Impact of sarcopenia on outcomes following intra-arterial therapy of hepatic malignancies. J Gastrointest Surg 2013;17:2123-32. [PMID: 24065364 DOI: 10.1007/s11605-013-2348-5] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 5.2] [Reference Citation Analysis]
16 Dong G, Lin XH, Liu HH, Gao DM, Cui JF, Ren ZG, Chen RX. Intermittent hypoxia alleviates increased VEGF and pro-angiogenic potential in liver cancer cells. Oncol Lett 2019;18:1831-9. [PMID: 31423251 DOI: 10.3892/ol.2019.10486] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
17 Zhang LJ, Zhang Z, Xu J, Jin N, Luo S, Larson AC, Lu GM. Carbogen gas-challenge blood oxygen level-dependent magnetic resonance imaging in hepatocellular carcinoma: Initial results. Oncol Lett. 2015;10:2009-2014. [PMID: 26622788 DOI: 10.3892/ol.2015.3526] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
18 Müller L, Stoehr F, Mähringer-Kunz A, Hahn F, Weinmann A, Kloeckner R. Current Strategies to Identify Patients That Will Benefit from TACE Treatment and Future Directions a Practical Step-by-Step Guide. J Hepatocell Carcinoma 2021;8:403-19. [PMID: 34012930 DOI: 10.2147/JHC.S285735] [Reference Citation Analysis]
19 Chiu SH, Chang PY, Shih YL, Huang WY, Ko KH, Chang WC, Huang GS. Efficacy and Safety of Supplemental Transarterial Chemoembolization Through Extrahepatic Collateral Arteries with Drug-eluting Beads: Treatment for Unresectable Hepatocellular Carcinoma. Drug Des Devel Ther 2020;14:5029-41. [PMID: 33235441 DOI: 10.2147/DDDT.S266470] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Boas FE, Kemeny NE, Sofocleous CT, Yeh R, Thompson VR, Hsu M, Moskowitz CS, Ziv E, Yarmohammadi H, Bendet A, Solomon SB. Bronchial or Pulmonary Artery Chemoembolization for Unresectable and Unablatable Lung Metastases: A Phase I Clinical Trial. Radiology 2021;301:474-84. [PMID: 34463550 DOI: 10.1148/radiol.2021210213] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 Popovic P, Stabuc B, Jansa R, Garbajs M. Survival of patients with intermediate stage hepatocellular carcinoma treated with superselective transarterial chemoembolization using doxorubicin-loaded DC Bead under cone-beam computed tomography control. Radiol Oncol 2016;50:418-26. [PMID: 27904450 DOI: 10.1515/raon-2015-0045] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
22 Park BV, Gaba RC, Lokken RP. Liver Infarction after Drug-Eluting Embolic Transarterial Chemoembolization for Hepatocellular Carcinoma in the Setting of a Large Portosystemic Shunt. Semin Intervent Radiol. 2016;33:337-341. [PMID: 27904254 DOI: 10.1055/s-0036-1592319] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
23 Szemitko M, Golubinska-Szemitko E, Wilk-Milczarek E, Falkowski A. Side Effect/Complication Risk Related to Injection Branch Level of Chemoembolization in Treatment of Metastatic Liver Lesions from Colorectal Cancer. J Clin Med 2020;10:E121. [PMID: 33396449 DOI: 10.3390/jcm10010121] [Reference Citation Analysis]